Pharmacokinetics of Switching Unboosted Atazanavir Coadministered with Tenofovir Disoproxil Fumarate from 400 Mg Once Daily to 200 Mg Twice Daily in HIV-Positive Patients
Free accessResearch articleFirst published online May, 2011
Pharmacokinetics of Switching Unboosted Atazanavir Coadministered with Tenofovir Disoproxil Fumarate from 400 Mg Once Daily to 200 Mg Twice Daily in HIV-Positive Patients
Use of unboosted atazanavir (ATV) with tenofovir disoproxil fumarate (TDF), although attractive from a clinical view point, has not been tested in trials and is not currently recommended because of the risk of suboptimal ATV pharmacokinetics (PK). In order to improve ATV exposure, plasma and intracellular (IC) PK of ATV in patients administered with ATV 400 mg once daily and TDF/emtricitabine (FTC) and switched to ATV 200 mg twice daily were studied.
Methods
On day 0, 10 subjects on ATV 400 mg plus TDF/FTC once daily underwent intensive plasma and IC PK evaluation and bilirubin measurement. Patients were subsequently switched to ATV 200 mg twice daily for 10 days. On day 11, they once again underwent intensive PK and bilirubin evaluation.
Results
Switch to 200 mg twice daily led (in plasma) to a significant increase of the observed concentration at the end of dosing interval (Ctrough; ratio twice daily/ once daily 2.20; P=0.005), with a decrease from 60% to 20% of suboptimal values, a significant decrease of the maximum concentration (Cmax; ratio twice daily/once daily 0.47; P=0.022), whereas no differences of other PK parameters or bilirubin were observed. IC ATV concentrations at 400 once daily showed higher Ctrough (ratio peripheral blood mononuclear cells [PBMCs]/plasma 2.86; P=0.005) and longer half-life (ratio PBMCs/ plasma 1.44; P=0.007) as compared with plasma. After the switch, IC ATV accumulation showed changes similar to plasma.
Conclusions
Switch to 200 mg twice daily appeared to optimize plasma and IC ATV PK, by increasing the determinant of efficacy (Ctrough) and decreasing Cmax, without significant effect on total ATV plasma exposure and bilirubin. Dosage of 200 mg might provide an option to patients showing suboptimal ATV exposure with standard unboosted dosing.
References
1.
Reyataz (atazanavir sulfate).Package insert2009. Bristol–Myers SquibbPrinceton, NJ, USA.
2.
Le TiecC., BarrailA., GoujardC., TaburetA.M.Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet2005; 44: 1035–1050.
3.
Panel on Antiretroviral Guidelines for Adult and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 1 December 2009. Accessed 7 July 2010.) Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
4.
DelfraissyJ.F., MorenoS., Sanz-MorenoJ.Efficacy and safety of 48-week maintenance with QD AT, V vs ATV/r (both + 2NRTIs) in patients with VL <50 c/mL after induction with ATV/r + 2NRTIs: study AI424136.9th International Congress on Drug Therapy in HIV Infection. 9–13 November 2008, Glasgow, UK. Abstract O415.
5.
SquiresK., YoungB., DeJesusE.Atazanavir/ritonavir + abacavir/lamivudine in antiretroviral-naive HIV-1 infected HLA-B*5701 negative subjects demonstrates efficacy and safety: the ARIES trial.48th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 25–28 October 2008, Washington, DC, USA. Abstract H-1250a.
6.
GiuntiniR., MartinelliC., RicciE.Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Med2010; 11: 40–45.
7.
MoltóJ., SantosJ.R., ValleM.Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther Drug Monit2007; 29: 648–651.
8.
CleijsenR.M., van de EndeM.E., KroonF.P.Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother2007; 60: 897–900.
9.
RayJ.E., MarriottD., BlochM.T., McLachlanA.J.Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol2005; 60: 291–299.
10.
D'AvolioA., BaiettoL., SiccardiM.An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit2008; 30: 662–669.
11.
ColomboS., BeguinA., TelentiA.Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci2005; 819: 259–276.
12.
D'AvolioA., SiccardiM., SciandraM.HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci2007; 859: 234–240.
13.
ColomboS., BuclinT., CavassiniM.Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother2006; 50: 3801–3808.
14.
MalanD.R., KrantzE., DavidN.Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr2008; 47: 161–167.
15.
Gonzalez de RequenaD., BonoraS., CantaF.Atazanavir Ctrough is associated with efficacy and safety: definition of therapeutic range.12th Conference on Retroviruses and Opportunistic Infections. 22–25 February 2005, Boston, MA, USA. Abstract 645.
BéïqueL., GiguèreP., la PorteC., AngelJ.Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Med2007; 8: 335–345.
18.
FordJ., BoffitoM., MaitlandD.Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. J Antimicrob Chemother2006; 58: 1009–1016.
19.
ColomboS., BuclinT., FrancC.Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Antivir Ther2006; 11: 53–62.
